CoChat

Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trial

Open access
Ratner, R. E., Rosenstock, J., Boka, G., on behalf of the DRI6012 Study Investigators · 2010 · Diabetic Medicine
Cited by 155

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Diabet. Med. 27, 1024–1032 (2010) Aims To evaluate the dose–response relationship of lixisenatide (AVE0010), a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in metformin‐treated patients with Type 2 diabetes. Methods Randomized, double‐blind, placebo‐controlled, parallel‐group, 13 week study of 542 patients with Type 2 diabetes inadequately controlled [glycated haemoglobin (HbA 1c) ≥ 7.0 and < 9.0% (≥ 53 and < 75 mmol/mol)] on metformin (≥ 1000 mg/day) treated with subcutaneous lixisenatide doses of 5, 10, 20 or 30 μg once daily or twice daily or placebo. The primary end‐point was change in HbA 1c from baseline to 13 weeks in the intent‐to‐treat population. Results Lixisenatide significantly improved mean HbA 1c from a baseline of 7.55% (59.0 mmol/mol); respective mean reductions for 5, 10, 20 and 30 μg doses were 0.47, 0.50, 0.69 and 0.76% (5.1, 5.5, 7.5 and 8.3 mmol/mol), on once‐daily and 0.65, 0.78, 0.75 and 0.87% (7.1, 8.5, 8.2 and 9.5 mmol/mol) on twice‐daily administrations vs. 0.18% (2.0 mmol/mol) with placebo (all P < 0.01 vs. placebo). Target HbA 1c < 7.0% (53 mmol/mol) at study end was achieved in 68% of patients receiving 20 and 30 μg once‐daily lixisenatide vs. 32% receiving placebo (P < 0.0001). Dose‐dependent improvements were observed for fasting, postprandial and average self‐monitored seven‐point blood glucose levels. Weight changes ranged from −2.0 to −3.9 kg with lixisenatide vs. −1.9 kg with placebo. The most frequent adverse event was mild‐to‐moderate nausea. Conclusions Lixisenatide significantly improved glycaemic control in mildly hyperglycaemic patients with Type 2 diabetes on metformin. Dose–response relationships were seen for once‐ and twice‐daily regimens, with similar efficacy levels, with a 20 μg once‐daily dose of lixisenatide demonstrating the best efficacy‐to‐tolerability ratio. This new, once‐daily GLP‐1 receptor agonist shows promise in the management of Type 2 diabetes to be defined further by ongoing long‐term studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2010.03020.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 155

Metadata

Authors
Ratner, R. E., Rosenstock, J., Boka, G., & on behalf of the DRI6012 Study Investigators
Venue
Diabetic Medicine
Publisher
Wiley
Published
2010-08-18
Volume
27
Issue
9
Pages
1024-1032
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1854533075
Cited by
155
References
9
FWCI
11.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/j.1464-5491.2010.03020.x
The paper
Ratner, R. E., Rosenstock, J., Boka, G., & on behalf of the DRI6012 Study Investigators. (2010). Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trial. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2010.03020.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.